New Lanier Biotherapeutics enters into licensing agreement with Alloy Therapeutics
Category: More news
Posted on Wednesday, 06 October 2021 17:33
Agreement marks official launch of Lanier, a Georgia-based biopharmaceutical company developing a strong portfolio of first-class antibody candidates
BOGART, GA, USA I 05 October 2021 I Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-class antibodies targeting the retina, dermatology and specialty type 2 inflammatory diseases, today announced that it has entered into an agreement to license (the “Agreement”) with Alloy Therapeutics (“Alloy”), a private drug discovery company.
Alloy to acquire AbeoMouse ™ and Direct Selection of Hybridomas (DiSH ™) antibody discovery technologies, which were originally developed by Abeome Corporation, Inc. (“Abeome”), one of two predecessor companies of Lanier. Upon closing of the agreement, Alloy will license to Lanier certain rights to AbeoMouse ™ and Alloy’s ATX-Gx ™ platform of proprietary transgenic mouse strains.
“We are delighted to enter into this mutually beneficial agreement, which provides the two companies with access to antibody discovery technologies while increasing our development pipeline and further strengthening our balance sheet,” said Kirby Alton, Chairman of the Board. by Lanier.
Lanier was recently formed by combining the activities of Abeome and Biophtha Inc., with bridge funding from investors, including founders Kirby Alton, PhD, former senior vice president of development at Amgen; and Daniel White, MBA, former CEO of Clearside Biomedical. MM. Alton and White are joined by Lanier’s other two founders, Martin Simonetti, MS, MBA and Chris McLeod, MS, to form Lanier’s experienced leadership team:
- President, CEO and Director Daniel White is an accomplished entrepreneur and visionary in the field of biotechnology and pharmacy. As the Founder and CEO of Clearside Biomedical, he led the company from inception of private funding until its IPO and brings a wealth of biomedical development and successful fundraising experience.
- President Kirby Alton returns to his role as President of Abeome and brings in-depth product development expertise gained as one of Amgen’s original scientists.
- The director, Martin Simonetti, has significant experience at Amgen and Genentech; a huge track record of leadership and growth in several biotechnology companies; and has successfully led private and capital market finance.
- The Director, Chris McLeod, is an experienced biotechnology executive with extensive expertise in growing companies and strategic collaborations. He is a former executive vice president of CuraGen and president of 454 Life Sciences; and is the current Managing Partner of Elm Street Ventures.
Lanier is developing a portfolio of 11 first-class therapeutic antibodies for diseases specializing in four major verticals: multifunctional retina, type 2 inflammation, dermatology and immuno-oncology.
“With a strong portfolio of 11 proprietary, first-class therapeutic antibodies, we look forward to moving forward into the clinic with our two lead candidates: anti IL25 to treat type 2 inflammatory disease,” said Daniel White, president and chief executive officer. direction of Lanier. “Lanier has launched a fundraiser to launch these two programs which promise to improve treatments in order to provide better lives for patients. “
Lanier’s LNR 653.1 is a proprietary bifunctional antibody developed for the treatment of retinal neovascularization diseases (age-related wet macular degeneration, diabetic macular edema and retinal venous occlusion. LNR 653.1 is designed to combine the anti-vascular effect. endothelial growth factor (VEGF) of aflibercept (marketed as Eylea by Regeneron) with anti-inflammatory and anti-apoptotic effects similar to those of secukinumab (marketed as Cosentyx by Novartis. Preclinical data suggests that NRL 653.1 is safe, with similar or greater efficacy to aflibercept. Lanier is currently conducting pre-formulation experiments and non-clinical functional testing, with plans to initiate experimental studies on a new drug (“IND” ) of LNR 653.1 in 2022.
Type 2 inflammation
LNR 125.38 is a monoclonal antibody that inhibits the upstream cytokine IL-25. By reducing or even eliminating the effects of allergic and antiviral cytokines downstream, LNR 125.38 targets type 2 inflammation, which is implicated in various atopic, allergic and inflammatory diseases. Lanier is prioritizing the development of LNR 125.38 in a wide range of potential treatments for moderate to severe asthma which is classified as high or low eosinophilic challenge by allergy or rhinovirus; chronic sinusitis with nasal polyps; and esophagitis and eosinophilic gastritis. Preclinical data demonstrated that LNR 125.38 significantly reduced type 2 (downstream) cytokines and inflammatory cells in asthma exacerbations induced by allergic mice and rhinovirus. Lanier is currently conducting pre-formulation experiments and non-clinical functional testing, with plans to initiate studies allowing IND of LNR 125.38 in the second half of 2022.
Lanier is developing LNR 653.1 for the treatment of psoriasis, where functional testing has shown comparable potency and efficacy to secukinumab and ixekizumab (marketed as Taltz by Eli Lilly). The Company is also developing LNR 125.38 for the treatment of chronic urticaria and atopic dermatitis.
MT-6402 is a toxin body manufactured by Molecular Templates, Inc., which contains a previously licensed PDL-1 inhibitor from Lanier’s extensive library of proprietary checkpoint inhibitors. In July, Molecular Templates administered the first subject of a Phase 1 study evaluating MT-6402 in patients with PD-L1 positive solid tumors and plans to provide an update on the study by the end. of this year.
About Alloy Therapeutics
Alloy Therapeutics is a biotech ecosystem company that empowers the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to the tools, technologies, services and business creation capabilities that are essential to the discovery and development of therapeutic biological products. The company facilitates affordable, non-exclusive access to the entire drug discovery community, from academic scientists, small and medium biotech to the largest biopharmaceutical companies. Alloy’s flagship offering, the ATX-Gx ™ platform, is a human therapeutic antibody discovery platform comprised of a growing suite of proprietary transgenic mouse strains. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with European laboratories in Cambridge, UK. Reflecting Alloy’s unwavering commitment to the scientific community, Alloy reinvests 100% of its turnover in innovation and access to innovation.
About AbeoMouse ™
AbeoMouse ™ is a new transgenic antibody discovery platform that generates mature B cells with high expression of surface immunoglobulins (Ig), allowing direct selection and cloning of antigen specific B cells. AbeoMouse ™ overexpresses immunoglobulin alpha (Ig- / CD79a), beta (Ig- / CD79b) co-receptors and interleukin 6 (IL6) genes, so that immunized animals produce a 45-fold increase in cells. secreting surface Ig positive antibodies and an accelerated immune response.
About DiSH ™
DiSH ™ The technology allows for the rapid selection and cloning of antigen-specific hybridomas. Using fluorescence activated cell sorting (FACS) or magnetic separation, desired hybridomas can be labeled and then isolated from a pool of hundreds of thousands of cells, within hours.
About Lanier Biotherapeutics
Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop a portfolio of first-class biologics for specialty diseases, with the ultimate goal of improving the way we survive, age and survive. to live. Lanier targets four major verticals: the multifunctional retina, type 2 inflammation, dermatology and immuno-oncology. Lanier’s main development programs include LNR 653.1, a fully humanized multi-functional anti-VEGF / IL-17A antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL-25 monoclonal antibody for the treatment of disease. inflammatory type 2. For more information, please visit www.lanierbio.com.
THE SOURCE: Lanier Biotherapeutics